People with TB Archives – Page 10 of 11

Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

January 24, 2017
Chad Cipiti

Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.

TAG Responds to the Release of the World Health Organization’s 2016 Global Tuberculosis Report

October 13, 2016
Chad Cipiti

TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated

Tuberculosis Research at Risk as Big Pharma Shutters Programs

October 22, 2014
Chad Cipiti

Worldwide governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group.

Letter Urging AstraZeneca to Continue to Invest in TB Research

February 13, 2014
Dorrit Walsh

February 13, 2014 TAG, CRAG, and the TB CAB sent an open letter to AstraZeneca urging their continued investment in tuberculosis research despite the cessation of AstraZeneca’s Neglected Tropical Diseases, Tuberculosis, and Malaria Program. Read/Download the TAG, CRAG, TB CAB…

Open Letter: Appreciation for Sanofi US Committing to Lower Price of Rifapentine

December 18, 2013
Dorrit Walsh

This letter from CRAG (TB Community Research Advisors Group) and TAG was sent to Anne Whitaker, President, North America Pharmaceuticals of Sanofi US. It commends Sanofi for making this commitment to lower the price of rifapentine for Public Health Service…

TAG, CRAG, and TB CAB Letter Calling for Compassionate Use Program for Delamanid

December 4, 2013
Dorrit Walsh

TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.

Roadmap for Childhood TB: Towards Zero Deaths

October 1, 2013
Chad Cipiti

The World Health Organization, the International Union Against Tuberculosis and Lung Disease, the Stop TB Partnership and other partners will launch a roadmap outlining the path towards zero deaths from childhood tuberculosis.

Treatment Action Group and the Stop TB Partnership Issue Update on 2011 Global TB R&D Investment Trends

November 14, 2012
Chad Cipiti

For the seventh year, Treatment Action Group (TAG) and the Stop TB Partnership have published the latest investment data on the state of global tuberculosis (TB) research and development (R&D) funding.

Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)

May 24, 2012
Chad Cipiti

May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…

Childhood TB Advocacy Meeting Presentations

January 12, 2012
Chad Cipiti

On January 5, 2012, TAG held a Childhood TB Federal Advocacy Meeting in Washington, D.C. The meeting was cosponsored by STOP TB, RESULTS/ACTION, the Center for Global Health Policy, and the American Thoracic Society (ATS). Some of the highlights of the…